Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
6
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
6
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
6
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
6
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
amgen
cancer
clinical trials
diagnostics
europe blog main
europe top stories
fda
hepatitis b
immunotherapy
medicaid
medicare
merck
microbiome
What
drug
6
×
bio
fda
market
new
patients
plan
roundup
acquisitions
advantages
agency
aimmune
allergy
anathema
approval
approved
awaited
awarded
bar
biggest
brings
build
buy
cancer
ceo
cholesterol
company’s
daniel
debut
democrat
details
developed
drugs
dyne’s
eisai
elements
expect
expensive
faces
financial
Language
unset
6
×
Current search:
drug
×
unset
×
" raleigh-durham blog main "
×
" life sciences "
×
" boston top stories "
×
" seattle top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)